clinical outcomes, ingredient by ingredient.
shown
Every active in the Encap system, traced to published evidence. No marketing claims, just the measured outcome and the citation behind it.
three steps to 3× deeper.
Each active is wrapped in a sub-micron, lipid-compatible shell, shielded from air, light and pH, so it arrives chemically intact instead of oxidising in the bottle.
The shell is engineered to cross the stratum corneum, the lipid layer that repels water-soluble actives and leaves conventional serums sitting on the surface.
Actives reach the layer where they act: fibroblasts for collagen, the follicle wall for clarity, released slowly rather than in a single irritating burst.
Reduction in total wrinkle surface area, with a 9.1% drop in wrinkle length, in just 14 days.
Improvement in microrelief structure and a 15% increase in epidermal thickness in post-menopausal skin.
Clinically equivalent to 0.5% retinol for wrinkle surface area and hyperpigmentation, with significantly higher tolerability.
Dose-dependent attenuation of oxidative stress (ROS) and stimulation of Type I collagen synthesis.
Mean reduction in acne severity scores (IGA) over 60 days, with zero adverse events recorded.
49.26% decrease in transepidermal water loss and a 23.65% reduction in surface sebum in 21 days.
200% increase in skin moisture and a 40% reduction in TEWL within 7 days via the Ectoin Hydrocomplex.
Comparable in clinical efficacy to 1.0% clindamycin for inflammatory acne, without antibiotic resistance.
marketing claims, removed.
Every figure is tied to a specific active at the concentration we use, never a finished-product halo claim.
Outcomes are drawn from published, peer-referenced studies, linked to the source wherever available.
Wrinkle area, TEWL, sebum, ATP, quantified endpoints, not adjectives or before-and-after lighting.
Ingredient- and population-level data informs expectations. It is not a guarantee of an individual outcome.